Heart Outcomes Prevention Evaluation-The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration

doi:10.1001/archopht.124.11.1665-a

You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.

Welcome | My Account | E-mail Alerts | Access Rights | Sign In

Vol. 124 No. 11, November 2006

Archives
	•	Online Features

Correspondence

This Article
•	Full text
•	PDF
•	Reply to article
•	Send to a friend
•	Save in My Folder
•	Save to citation manager
•	Permissions

Citing Articles
•	Contact me when this article is cited

Related Content
•	Related letter
•	Related article
•	Similar articles in this journal

Topic Collections
•	Aging/ Geriatrics
•	Nutritional and Metabolic Disorders
•	Nutrition/ Malnutrition
•	Macular Degeneration
•	Cardiovascular System
•	Prognosis/ Outcomes
•	Cardiovascular Disease/ Myocardial Infarction
•	Congestive Heart Failure/ Cardiomyopathy
•	Alert me on articles by topic

Social Bookmarking
	What's this?

Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent editorial regarding the use of vitamin E for age-relatedmacular degeneration, Chew and Clemons stated:

For these reasons, combined with little evidence from the meta-analysisof harm at the 400 IU/d dosage, we do not think there is increasedrisk of mortality associated with the AREDS [Age-Related EyeDisease Study] supplements that include 400 IU/d of vitaminE.¹

Further, last year I questioned the use of high doses of vitaminsE and C because of a study that showed that high doses wereassociated with heart disease in women.² The response from Ferrisand Milton³ was that the doses were higher than those used inthe AREDS. Ferris and Milton also stated:

We know of no clear indication of increased risk of cardiovasculardisease with the doses of vitamins C or E used in AREDS or inpatients similar to the AREDS population.³

I wonder whether Chew . . . [Full Text of this Article]

AUTHOR INFORMATION
Jose S. Pulido, MD

Add to CiteULike CiteULike Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

RELATED LETTER

Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration—Reply
Emily Y. Chew and Traci E. Clemons
Arch Ophthalmol. 2006;124(11):1665-1666.
EXTRACT | FULL TEXT

RELATED ARTICLE

Vitamin E and the Age-Related Eye Disease Study Supplementation for Age-Related Macular Degeneration
Emily Y. Chew and Traci Clemons
Arch Ophthalmol. 2005;123(3):395-396.
EXTRACT | FULL TEXT

| | |